CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 94 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02635360
NCT02635360Phase 2Completed
CompareCT.gov

A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer

Linda R Duska·interventional·Posted Dec 18, 2015·Updated Jul 3, 2025

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab, Brachytherapy, and 1 other intervention for Cervical Cancer. Completed, enrolled 94 participants across 8 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 18, 2015
Enrollment StartFeb 9, 2017
Primary CompletionJan 1, 2021
Study CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.5 years ago

Interventions

Pembrolizumabdrug

200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.

Brachytherapyradiation

Radiation is done for standard clinical care purposes.

Cisplatindrug

40 mg of chemotherapy drug will be given weekly for 5-6 weeks.